trending Market Intelligence /marketintelligence/en/news-insights/trending/cl_vccdbhqf3gan-tqxt6w2 content esgSubNav
In This List

CytoDyn appoints board chairman

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


CytoDyn appoints board chairman

CytoDyn Inc. appointed Scott Kelly as board chairman.

Kelly, who has served as a member of the company's board since April 2017, succeeds Anthony Caracciolo, who will continue as a director.

Vancouver, Wash.-based CytoDyn develops humanized monoclonal antibodies to treat and prevent HIV infection.